Information Provided By:
Fly News Breaks for December 31, 2019
ZYNE
Dec 31, 2019 | 08:24 EDT
Roth Capital analyst Scott Henry assumed coverage of Zynerba with a Buy rating and $12 price target saying the company is an emerging pharmaceutical company focused on cannabinoids. The analyst highlights the company's four key program approaching either clinical readouts or FDA meetings in first half 2020, and believes expectations are low, creating a compelling risk/reward for investors.
News For ZYNE From the Last 2 Days
There are no results for your query ZYNE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.